Recruitment

Recruitment Status
Completed
Estimated Enrollment
150

Inclusion Criteria

Assumed good cooperation and social background
Signed informed consent
Haemodynamic and rhythmic stability (Killip class I, no arrythmia requiring treatment occurring > 2 hours after PCI)
...
Assumed good cooperation and social background
Signed informed consent
Haemodynamic and rhythmic stability (Killip class I, no arrythmia requiring treatment occurring > 2 hours after PCI)
Left ventricle ejection fraction ≥ 45% by echocardiography
Acute myocardial infarction with ST-segment elevation, treated with successful percutaneous coronary intervention within 12 hours from the onset of symptoms
Age ≥18 do ≤ 75 years
Single- or two-vessel disease (stenosis of major epicardial artery ≥ 70%)

Exclusion Criteria

Significant comorbidities or abnormalities in paraclinical tests, requiring additional evaluation within continuing hospitalization
Contraindication of dual antiplatelet therapy or need for anticoagulation therapy
Symptoms of residual ischemia
...
Significant comorbidities or abnormalities in paraclinical tests, requiring additional evaluation within continuing hospitalization
Contraindication of dual antiplatelet therapy or need for anticoagulation therapy
Symptoms of residual ischemia
Hihg risk of bleeding complications
Participation in other clinical study

Summary

Conditions
  • Acute Myocardial Infarction With ST-segment Elevation
  • Coronary (Artery) Disease
  • Early Discharge
  • Primary Percutaneous Coronary Intervention
  • Coronary Artery Disease
Type
Interventional
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Other

Participation Requirements

Age
Between 18 years and 75 years
Gender
Both males and females

Description

The aim of the study is to prove that early discharge (within 72 hours) in selected group of patients with low risk of follow-up complications after myocardial infarction with elevations of ST-segment, treated with primary percutaneous coronary intervention, is feasible and safe that early discharge...

The aim of the study is to prove that early discharge (within 72 hours) in selected group of patients with low risk of follow-up complications after myocardial infarction with elevations of ST-segment, treated with primary percutaneous coronary intervention, is feasible and safe that early discharge is comparable with the group of patients, discharged in a standard way accordingly with present practice and physician´s decision (usually 4th-7th day), thus it is not associated with higher incidence of complications in 90th day after myocardial infarction

Inclusion Criteria

Assumed good cooperation and social background
Signed informed consent
Haemodynamic and rhythmic stability (Killip class I, no arrythmia requiring treatment occurring > 2 hours after PCI)
...
Assumed good cooperation and social background
Signed informed consent
Haemodynamic and rhythmic stability (Killip class I, no arrythmia requiring treatment occurring > 2 hours after PCI)
Left ventricle ejection fraction ≥ 45% by echocardiography
Acute myocardial infarction with ST-segment elevation, treated with successful percutaneous coronary intervention within 12 hours from the onset of symptoms
Age ≥18 do ≤ 75 years
Single- or two-vessel disease (stenosis of major epicardial artery ≥ 70%)

Exclusion Criteria

Significant comorbidities or abnormalities in paraclinical tests, requiring additional evaluation within continuing hospitalization
Contraindication of dual antiplatelet therapy or need for anticoagulation therapy
Symptoms of residual ischemia
...
Significant comorbidities or abnormalities in paraclinical tests, requiring additional evaluation within continuing hospitalization
Contraindication of dual antiplatelet therapy or need for anticoagulation therapy
Symptoms of residual ischemia
Hihg risk of bleeding complications
Participation in other clinical study

Tracking Information

NCT #
NCT02023983
Collaborators
Not Provided
Investigators
Not Provided
About Us
Innovation
Privacy
Terms
Copyright
Get Well Soon © Copyright 2023